Liverpool have opened talks with Crystal Palace over a deal for Marc Guehi, with negotiations focusing on a fee of around £35 ...

Should you look for sharpshooters like Bayer Leverkusen's Patrik Schick and Eintracht Frankfurt's Jonathan Burkardt to lead your Fantasy Bundesliga line or are you willing to place your faith in an ...

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

Serie A Defender on the RadarThe summer transfer window is always a pivotal time for football clubs, and Liverpool are ...

Small bands of Russian soldiers thrust deeper into eastern Ukraine on Tuesday ahead of a summit this week between Russian ...

Cristiano Ronaldo demanded a contract clause to return to Manchester United in 2021 and it's one that could cost Chelsea in the future ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

Liverpool are keen on continuing their summer transfer spending spree with a swoop for England international Marc Guehi ...

MANCHESTER UNITED are in for an absolutely massive summer of transfer business at Old Trafford! The Red Devils reportedly ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug.

Today’s White House MAHA Commission report is expected to pull punches on pesticide regulation as Bayer lobbies to limit ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...